The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Site Search
Marissa Benchea and Jeremy and Rachel Olimb to lead the Foundation’s volunteer advocacy base into a new chapter of CF
I’ve had to make many changes in response to the COVID-19 pandemic to protect my health. Not all the changes were welcome, but now that I’ve adjusted, I’m enjoying my new normal.
The studies aim to improve early detection of chronic lung allograft dysfunction (CLAD), the leading cause of lung transplant failures.
Although I had been told that my coughing would stop, I wish I had known more about the transformative change that Trikafta® would have on my life. It has almost made me wistful for the time when I was sick, back when I was more in tune with what my body was experiencing.
The journey my husband and I traveled while trying to conceive our son was stressful but ultimately fruitful. Here’s what I learned during that process.
Early stage researchers, life science entrepreneurs, and companies are encouraged to apply starting May 2
New modulators in development by the CF-specific company could provide unique treatment options for the underlying cause of cystic fibrosis for many people with the disease
Proposed legislation has the potential to revitalize the global marketplace for novel antibiotics, bringing urgently needed medicines for drug-resistant infections to patients.
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance